Explainable Machine Learning Model to Predict Overall Survival in Patients Treated With Palliative Radiotherapy for Bone Metastases

• Published in: JCO clinical cancer informatics Vol. 8; p. e2400027
• Main Authors: Cilla, Savino, Rossi, Romina, Habberstad, Ragnhild, Klepstad, Pal, Dall'Agata, Monia, Kaasa, Stein, Valenti, Vanessa, Donati, Costanza M, Maltoni, Marco, Morganti, Alessio G
• Format: Journal Article
• Language: English
• Published: United States 01-06-2024
• Subjects: Aged; Algorithms; Bone Neoplasms - mortality; Bone Neoplasms - radiotherapy; Bone Neoplasms - secondary; Female; Humans; Machine Learning; Male; Middle Aged; Palliative Care - methods; Prognosis
• ISSN: 2473-4276
• DOI: 10.1200/CCI.24.00027

The estimation of prognosis and life expectancy is critical in the care of patients with advanced cancer. To aid clinical decision making, we build a prognostic strategy combining a machine learning (ML) model with explainable artificial intelligence to predict 1-year survival after palliative radiotherapy (RT) for bone metastasis.
Data collected in the multicentric PRAIS trial were extracted for 574 eligible adults diagnosed with metastatic cancer. The primary end point was the overall survival (OS) at 1 year (1-year OS) after the start of RT. Candidate covariate predictors consisted of 13 clinical and tumor-related pre-RT patient characteristics, seven dosimetric and treatment-related variables, and 45 pre-RT laboratory variables. ML models were developed and internally validated using the Python package. The effectiveness of each model was evaluated in terms of discrimination. A Shapley Additive Explanations (SHAP) explainability analysis to infer the global and local feature importance and to understand the reasons for correct and misclassified predictions was performed.
The best-performing model for the classification of 1-year OS was the extreme gradient boosting algorithm, with AUC and F1-score values equal to 0.805 and 0.802, respectively. The SHAP technique revealed that higher chance of 1-year survival is associated with low values of interleukin-8, higher values of hemoglobin and lymphocyte count, and the nonuse of steroids.
An explainable ML approach can provide a reliable prediction of 1-year survival after RT in patients with advanced cancer. The implementation of SHAP analysis provides an intelligible explanation of individualized risk prediction, enabling oncologists to identify the best strategy for patient stratification and treatment selection.